
Photo from Aakash Desai/LinkedIn
Sep 13, 2024, 12:06
Aakash Desai: The biomarker landscape of ADCs and bispecific antibodies (BsAbs) in Lung cancer
Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared on LinkedIn:
“Excited to share the findings from our study on the biomarker landscape of antibody-drug conjugates (ADCs) and bispecific antibodies (BsAbs) in clinical trials for Lung Cancer at WCLC24!
Biomarker Landscape in Lung Cancer Clinical Trials
Key insights:
• 47 clinical trials reviewed
• Biomarkers are crucial in ADC/BsAb trials, with 45% including biomarkers
• EGFR, MET, and TROP2 among the top biomarkers identified !”
Source: Aakash Desai/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 10:07
Feb 21, 2025, 09:58
Feb 21, 2025, 09:54
Feb 21, 2025, 09:45
Feb 21, 2025, 09:35
Feb 21, 2025, 09:18
Feb 21, 2025, 09:07
Feb 21, 2025, 09:00
Feb 21, 2025, 08:19